SEARCH

SEARCH BY CITATION

References

  • 1
    Ferlay J, Shin HR, Bray F et al.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer2010; 127: 2893917.
  • 2
    Cancer Research UK. Bladder cancer statistics – key facts. http://info.cancerresearchuk.org/cancerstats/keyfacts/bladder-cancer/ (accessed June 2012).
  • 3
    Fajkovic H, Halpern JA, Cha EK et al.Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol2011; 29: 45763.
  • 4
    Edwards BK, Ward E, Kohler BA et al.Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer2010; 116: 54473.
  • 5
    Bosetti C, Bertuccio P, Chatenoud L et al.Trends in mortality from urologic cancers in Europe, 1970–2008. Eur Urol2011; 60: 115.
  • 6
    Qiu D, Katanoda K, Marugame T, Sobue T. A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958–2004). Int J Cancer2009; 124: 4438.
  • 7
    Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for bladder cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med2011; 155: 24651.
  • 8
    Keegan KA, Resnick MJ, Clark PE. Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder. Curr Opin Oncol2012; 24: 27883.
  • 9
    British Association of Urological Surgeons, Section of Oncology. BAUS Cancer Registry, analyses of minimum data set for urological cancers, January to December 2009. October 2010. http://www.baus.org.uk/Resources/BAUS/Documents/PDF%20Documents/Data%20and%20Audit/2009finalanalyses.pdf (accessedJune 2012).
  • 10
    Yafi FA, Aprikian AG, Chin JL et al.Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int2011; 108: 53945.
  • 11
    Gouda I, Mokhtar N, Bilal D, El-Bokhainy T, El-Bokhainy NM. Bilharziasis and bladder cancer: a time trend analysis of 9843 patients. J Egypt Natl Canc Inst2007; 19: 15862.
  • 12
    Felix AS, Soliman AS, Khaled H et al.The changing patterns of bladder cancer in Egypt over the past 26 years. Cancer Causes Control2008; 19: 4219.
  • 13
    Stenzl A, Witjes JA, Cowan NC, et al.European Association of Urology Guidelines on muscle invasive and metastatic bladder cancer 2011. http://www.uroweb.org/gls/pdf/07_%20Bladder%20Cancer.pdf (accessed June 2012).
  • 14
    Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA2011; 306: 73745.
  • 15
    Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer2000; 89: 6309.
  • 16
    Baris D, Karagas MR, Verrill C et al.A case-control study of smoking and bladder cancer risk: emergent patterns over time. J Natl Cancer Inst2009; 101: 155361.
  • 17
    Hartge P, Silverman D, Hoover R et al.Changing cigarette habits and bladder cancer risk: a case-control study. J Natl Cancer Inst1987; 78: 111925.
  • 18
    Kogevinas M, Mannetje A, Cordier S et al.Occupation and bladder cancer among men in Western Europe. Cancer Causes Control2003; 14: 90714.
  • 19
    Chen CJ, Chuang YC, Lin TM, Wu HY. Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res1985; 45: 58959.
  • 20
    Marcus PM, Vineis P, Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics2000; 10: 11522.
  • 21
    García-Closas M, Malats N, Silverman D. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet2005; 366: 64959.
  • 22
    Lee SW, Jang IJ, Shin SG et al.CYP1A2 activity as a risk factor for bladder cancer. J Korean Med Sci1994; 9: 4829.
  • 23
    Kiemeney L, Thorlacius S, Sulem P et al.Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet2008; 40: 130712.
  • 24
    Duncan RE, Bennett DW, Evans AT, Aron BS, Schellhas HF. Radiation-induced bladder tumors. J Urol1977; 118: 435.
  • 25
    Sella A, Dexeus FH, Chong C, Ro JY, Logothetis CJ. Radiation therapy-associated invasive bladder tumors. Urology1989; 33: 1858.
  • 26
    Turina M, Mulhall AM, Mahid SS, Yashar C, Galandiuk S. Frequency and surgical management of chronic complications related to pelvic irradiation. Arch Surg2008; 143: 4652.
  • 27
    Moon K, Stukenborg GJ, Keim J, Theodorescu D. Cancer incidence after localized therapy for prostate cancer. Cancer2006; 107: 9918.
  • 28
    Fairchild WV, Spence CR, Solomon HD, Gangai MP. The incidence of bladder cancer after cyclophosphamide therapy. J Urol1979; 122: 1634.
  • 29
    Pedersen-Bjergaard J, Ersboll J, Hansen VL et al.Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin’s lymphoma. N Engl J Med1988; 318: 102832.
  • 30
    Travis LB, Curtis RE, Glimelius B et al.Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J Natl Cancer Inst1995; 87: 52430.
  • 31
    Knight A, Askling J, Granath F, Sparen P, Ekbom A. Urinary bladder cancer in Wegener’s granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis2004; 63: 130711.
  • 32
    Links M, Lewis C. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy. Drugs1999; 57: 293308.
  • 33
    Fokkens W. Phenacetin abuse related to bladder cancer. Environ Res1979; 20: 1928.
  • 34
    Castelao JE, Yuan J-M, Gago-Dominguez M, Yu MC, Ross RK. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer2000; 87: 13649.
  • 35
    Fortuny J, Kogevinas M, Zens MS et al.Analgesic and anti-inflammatory use and risk of bladder cancer: a population based case-control study. BMC Urol2007; 7: 13.
  • 36
    Genkinger JM, De Vivo I, Stampfer MJ, Giovannucci E, Michaud DS. Nonsteroidal anti-inflammatory drug use and risk of bladder cancer in the health professionals follow-up study. Int J Cancer2007; 120: 22215.
  • 37
    Dormandy JA, Charbonnel B, Eckland DJ et al.Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular. Lancet2005; 366: 127989.
  • 38
    Lewis JD, Ferrara A, Peng T et al.Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care2011; 34: 91622.
  • 39
    Nortier JL, Martinez MC, Schmeiser HH et al.Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med2000; 342: 168692.
  • 40
    Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol2000; 163: 5247.
  • 41
    Edwards TJ, Dickinson AJ, Gosling J et al.Patient-specific risk of undetected malignant disease after investigation for haematuria, based on a 4-year follow-up. BJU Int2011; 107: 24752.
  • 42
    Renal Association and British Association of Urological Surgeons. Joint consensus statement on the initial assessment of haematuria. July 2008. http://www.baus.org.uk/AboutBAUS/publications/haematuria-guidelines (accessed June 2012).
  • 43
    Kelly JD, Fawcett DP, Goldberg LC. Assessment and management of non-visible haematuria in primary care. BMJ2009; 338: 22732.
  • 44
    Davis R, Jones JS, Barocas DA, et al.Diagnosis, evaluation and follow-up of asymptomatic microhaematuria (AMH) in adults: AUA Guideline. http://www.auanet.org/content/media/asymptomatic_microhematuria_guideline.pdf (accessed October 2012)
  • 45
    Chung A, Arianayagam M, Rashid P. Bacterial cystitis in women. Aust Fam Physician2010; 39: 2958.
  • 46
    Jones GR, Newhouse IJ, Jakobi JM, LaVoie NL, Thayer R. The incidence of hematuria in middle distance track running. Can J Appl Physiol2001; 26: 33649.
  • 47
    Van Savage JG, Fried FA. Anticoagulant associated haematuria: a prospective study. J Urol1995; 153: 15946.
  • 48
    Hurlen M, Eikvar L, Seljeflot I, Arnesen H. Occult bleeding in three different antithrombotic regimes after myocardial infarction. A WARIS-II-subgroup analysis. Thromb Res2006; 118: 4338.
  • 49
    Edwards TJ, Dickinson AJ, Natale S, Gosling J, McGrath JS. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int2006; 97: 3015.
  • 50
    Hiatt RA, Ordoñez JD. Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample. Cancer Epidemiol Biomarkers Prev1994; 3: 43943.
  • 51
    National Institute for Health and Clinical Excellence. Referral guidelines for suspected cancer. http://www.nice.org.uk/nicemedia/pdf/CG027publicinfo.pdf (accessed June 2012).
  • 52
    Raitanen MP, Leppilahti M, Tuhkanen K et al.Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer. Ann Chir Gynaecol2001; 90: 2615.
  • 53
    Isfoss BL. The sensitivity of fluorescent-light cystoscopy for the detection of carcinoma in situ (CIS) of the bladder: a meta-analysis with comments on gold standard. BJU Int2011; 108: 17037.
  • 54
    Mowatt G, Zhu S, Kilonzo M et al.Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess2010; 14: 1331, iii–iv.
  • 55
    Mowatt G, N’Dow J, Vale L et al.Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int J Technol Assess Health Care2011; 27: 310.
  • 56
    Kausch I, Sommerauer M, Montorsi F et al.Photodynamic diagnosis in non-muscle invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur Urol2010; 57: 595606.
  • 57
    Schumacher MC, Davidsson T, Friedrich B et al.Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective randomized multicentre study. Eur Urol2010; 57: 2939.
  • 58
    Stenzl A, Burger M, Fradet Y et al.Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol2010; 184: 190713.
  • 59
    Hermann GG, Mogensen K, Carlsson S, Marcussen N, Duun S. Fluorescence-guided transurethral resection of bladder tumours reduces bladder tumour recurrence due to less residual tumour tissue in Ta/T1 patients: a randomized two-centre study. BJU Int2011; 108(8 Pt 2): E297303.
  • 60
    Stenzl A, Penkoff H, Dajc-Sommerer E et al.Detection and clinical outcome of urinary bladder cancer with 5-aminolevulinic acid-induced fluorescence cystoscopy: a multicenter randomized, double-blind, placebo-controlled trial. Cancer2011; 117: 93847.
  • 61
    Cauberg ECC, Kloen S, Visser M et al.Narrow band imaging cystoscopy improves the detection of non-muscle-invasive bladder cancer. Urology2010; 76: 65863.
  • 62
    Herr HW, Donat SM. Reduced bladder tumour recurrence rate associated with narrow-band imaging surveillance cystoscopy. BJU Int2011; 107: 3968.
  • 63
    Sylvester RJ, van der Meijden APM, Oosterlinck W et al.Predicting recurrence and progression in individual patients with Stage Ta T1 bladder cancer using EORTC Risk Tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol2006; 49: 46677.
  • 64
    Mariappan P, Finney SM, Head E et al.Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int2012; 109: 166673.
  • 65
    Brausi M, Collette L, Kurth K et al.Variability in the recurrence rate at first follow-up cystoscopy after TUR in Stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol2002; 41: 52331.
  • 66
    Babjuk M, Oosterlinck W, Sylvester R, et al.European Association of Urology Guidelines on non-muscle invasive bladder cancer (TaT1 and CIS) 2011. http://www.uroweb.org/gls/pdf/05_TaT1_Bladder_Cancer.pdf (accessed June 2012).
  • 67
    Dalbagni G, Vora K, Kaag M et al.Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol2009; 56: 90310.
  • 68
    Herr HW, Donat SM. Quality control in transurethral resection of bladder tumours. BJU Int2008; 102: 12426.
  • 69
    Schips L, Augustin H, Zigeuner RE et al.Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?Urology2002; 59: 2203.
  • 70
    Sylvester RJ, Oosterlinck W, van der Meijden APM. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol2004; 171: 218690.
  • 71
    Kaasinen E, Rintala E, Hellström P et al.Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol2002; 42: 16774.
  • 72
    Hinotsu S, Akaza H, Ohashi Y, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer1999; 86: 181826.
  • 73
    Pawinski A, Sylvester R, Kurth KH et al.A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol1996; 156: 193440.
  • 74
    Malmstrom P-U, Sylvester RJ, Crawford DE et al.An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol2009; 56: 24756.
  • 75
    Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol2002; 168: 196470.
  • 76
    Böhle A, Bock PR. Intravesical bacille calmette-guérin versus mitomycin c in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology2004; 63: 6826.
  • 77
    Sylvester RJ, Brausi MA, Kirkels WJ et al.Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol2010; 57: 76673.
  • 78
    Brausi MA, Oddens JR, Sylvester RJ et al.Bacillus Calmette-Guerin: one third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer. 27th Annual Congress of the European Association of Urology, February 2012. Abstract 1050.
  • 79
    Lamm DL, Blumenstein BA, Crissman JD et al.Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol2000; 163: 11249.
  • 80
    Griffiths TRL, Charlton M, Neal DE, Powell PH. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol2002; 167: 240812.
  • 81
    Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?J Urol2007; 177: 759.
  • 82
    Kulkarni GS, Hakenberg OW, Gschwend JE et al.An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol2010; 57: 6070.
  • 83
    Denzinger S, Fritsche H-M, Otto W et al.Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?Eur Urol2008; 53: 14652.
  • 84
    Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?J Urol2001; 166: 12969.
  • 85
    Samaratunga H, Khoo K. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study. Histopathology2004; 45: 5564.
  • 86
    Kamat AM, Dinney CP, Gee JR et al.Micropapillary bladder cancer: a review of the University of Texas M.D. Anderson Cancer Center experience with 100 consecutive patients. Cancer2007; 110: 627.
  • 87
    Palou J, Rodriguez-Rubio F, Huguet J et al.Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumour. J Urol2005; 174: 85961.
  • 88
    Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Huguet-Perez J, Vicente-Rodriguez J. Upper urinary tract tumours after primary superficial bladder tumours: prognostic factors and risk groups. J Urol2000; 164: 11837.
  • 89
    O’Brien T, Ray E, Singh R, Coker B, Beard R, British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative dose of mitomycin C (the ODMIT-C trial). Eur Urol2011; 60: 70310.
  • 90
    Yates DR, Roupret M. Failure of bacille Calmette-Guerin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options. BJU Int2010; 106: 1627.
  • 91
    Shen Z, Shen T, Wientjes MG, O’Donnell MA, Au JL. Intravesical treatments of bladder cancer: review. Pharm Res2008; 25: 150010.
  • 92
    Lammers RJM, Witjes JA, Inman BA et al.The role of a combined regimen with intravesical chemotherapy in the management of non-muscle invasive bladder cancer: a systematic review. Eur Urol2011; 60: 8193.
  • 93
    Witjes JA, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol2009; 27: 31924.
  • 94
    Nativ O, Witjes JA, Hendricksen K et al.Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol2009; 182: 13137.
  • 95
    Di Stasi SM, Giannantoni A, Stephen RL et al.Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol2003; 170: 77782.
  • 96
    Di Stasi SM, Valenti M, Verri C et al.Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial. Lancet Oncol2011; 12: 8719.
  • 97
    Birkmeyer NJ, Goodney PP, Stukel TA, Hillner BE, Birkmeyer JD. Do cancer centres designated by the National Cancer Institute have better surgical outcomes?Cancer2005; 103: 43541.
  • 98
    Horwich A, Dearnaley D, Huddart R et al.A randomized trial of accelerated radiotherapy for localized invasive bladder cancer. Radiother Oncol2005; 75: 3443.
  • 99
    Ficarra V, Dalpiaz O, Alrabi N, Novara G, Galfano A, Artibani W. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int2005; 95: 78690.
  • 100
    Madersbacher S, Hochreiter W, Burkhard F et al.Radical cystectomy for bladder cancer today – a homogeneous series without neoadjuvant therapy. J Clin Oncol2003; 21: 6906.
  • 101
    Cowan R, McBain C, Ryder WD et al.Radiotherapy for muscle invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys2004; 59: 197207.
  • 102
    Kotwal S, Choudhury A, Johnston C et al.Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment centre. Int J Radiat Oncol Biol Phys2008; 70: 45663.
  • 103
    Addla SK, Naidu P, Maddineni SB, Ramani VA. Long term survival outcome following radical cystectomy for TCC of the bladder – comparison between primary and salvage cystectomy. J Urol2009; 4(Suppl): 633. Abstract 1754.
  • 104
    Schuster TG, Smith DC, Montie JE. Pelvic recurrences post cystectomy: current treatment strategies. Semin Urol Oncol2001; 19: 4550.
  • 105
    Stein JP, Skinner DG. Results with radical cystectomy for treating bladder cancer: a ‘reference standard’ for high grade invasive bladder cancer. BJU Int2003; 92: 127.
  • 106
    Liberman D, Lughezzani G, Sun M et al.Perioperative mortality is significantly greater in septagenarian and octogenarian patients treated with radical cystectomy for urothelial cancer of the bladder. Urology2011; 77: 6606.
  • 107
    Lowrance WT, Rumohr JA, Chang SS, Smith JA Jr, Cookson MS. Contemporary open radical cystectomy: analysis of perioperative outcomes. J Urol2008; 179: 13138.
  • 108
    Shabsigh A, Korets R, Vora KC et al.Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol2009; 55: 16474.
  • 109
    Herr HW. Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology2003; 61: 1058.
  • 110
    Burkhard FC, Roth B, Zehnder P, Studer UE. Lymphadenectomy for bladder cancer: indications and controversies. Urol Clin North Am2011; 38: 397405.
  • 111
    Novara G, Svatek RS, Karakiewicz PI et al.Soft tissue surgical margin status is a powerful predictor of outcomes after radical radiotherapy: a multicentre study of more than 4400 patients. J Urol2010; 183: 216570.
  • 112
    International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), the European Organisation for Research and Treatment of Cancer Genito-urinary Tract Cancer Group et al.International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle invasive bladder cancer; long-term results of the BA06 30894 Trial. J Clin Oncol2011; 29: 21717.
  • 113
    Advanced Bladder Cancer (ABC) Meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol2005; 48: 2025.
  • 114
    Sherif A, Holmberg L, Rintala E et al. Nordic Urothelial Cancer GroupNeoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol2004; 45: 297303.
  • 115
    Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol2010; 28: 49128.
  • 116
    James ND, Hussain SA, Hall E et al.Radiotherapy with or without chemotherapy in muscle invasive bladder cancer. N Engl J Med2012; 366: 147788.
  • 117
    Choudhury A, Swindell R, Logue JP et al.Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol2011; 29: 7338.
  • 118
    Somani BK, Gimlin D, Fayers P, N’Dow J. Quality of life and body image for bladder cancer patients undergoing radical cystectomy and urinary diversion – a prospective cohort study with a systematic review of literature. Urology2009; 74: 113843.
  • 119
    Caffo O, Fellin G, Graffer U, Luciani L. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire. Cancer1996; 78: 108997.
  • 120
    Zietman AL, Sacco D, Skowronski U et al.Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol2003; 170: 17726.
  • 121
    von der Maase H, Sengelov L, Roberts JT et al.Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin with methotrexate, vinblastine, doxorubicin plus cisplatin in patients with bladder cancer. J Clin Oncol2005; 23: 46028.
  • 122
    Zaghloul MS, Boutrus R, El-Hossieny H et al.A prospective randomized placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol2010; 15: 3829.